Status:
UNKNOWN
Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer
Lead Sponsor:
Georgia Center for Oncology Research & Education
Collaborating Sponsors:
Sanofi
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to identify new chemotherapy treatment regimens with better response rates and to find out if the combination of docetaxel and capecitabine can shrink the size of breast t...
Detailed Description
The purpose of this study is to identify new chemotherapy treatment regimens with better response rates and to find out if the combination of docetaxel and capecitabine can shrink the size of breast t...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed breast carcinoma.
- Early stage breast cancer (stage 1, 2, 3).
- No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes.
- 18 years of age or older.
- Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
Exclusion
- Prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast cancer.
- Major surgery within 28 days of study entry.
- Evidence of CNS metastases.
- Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00415285
Start Date
December 1 2006
Last Update
February 13 2007
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Grady Memorial Hospital
Atlanta, Georgia, United States, 30303
2
Emory Crawford Long Hospital
Atlanta, Georgia, United States, 30308
3
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States, 30322